Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $25.14
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 18, 26 |
Daily · Wilder smoothing
| Barclays |
| maintain |
| Equal Weight |
| Equal Weight |
| Aug 7, 26 | Piper Sandler | maintain | Neutral | Neutral |
| Aug 7, 26 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Jun 29, 26 | B of A Securities | downgrade | Neutral | Underperform |
| Jun 3, 26 | Barclays | maintain | Equal Weight | Equal Weight |
| May 14, 26 | Wells Fargo | downgrade | Overweight | Equal Weight |
| May 11, 26 | Piper Sandler | maintain | Neutral | Neutral |
| May 8, 26 | Needham | downgrade | Buy | Hold |
| Apr 21, 26 | Jefferies | downgrade | Buy | Hold |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 47.47 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 42.09 | Oscillator | Neutral |
| Williams %R (14) | -79.03 | Oscillator | Neutral |
| MACD (12, 26, 9) | 0.43 (Hist -0.20) | Oscillator | Sell |
| Average Directional Index (14) | 38.51 (+DI 21.5 / -DI 23.9) | Trend | Strong Sell |
| EMA 20 | 25.70 | MA | Sell |
| SMA 20 | 26.03 | MA | Strong Sell |
| EMA 50 | 24.40 | MA | Strong Buy |
| SMA 50 | 24.25 | MA | Strong Buy |
| SMA 200 | 22.29 | MA | Strong Buy |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 21, 26 | Peters William J | director, officer: CFO, EVP & TREASURER | S-Sale | 4,139 @ $25.00 | $103.5K |
| Sep 16, 26 | Zhou Rong | officer: SENIOR EVP, PRODUCTION CENTER | M-Exempt | 10,000 @ $13.35 | $133.5K |
| Sep 16, 26 | Zhou Rong | officer: SENIOR EVP, PRODUCTION CENTER | S-Sale | 10,000 @ $23.94 | $239.4K |
| Sep 16, 26 | Zhou Rong | officer: SENIOR EVP, PRODUCTION CENTER | M-Exempt | 10,000 @ $13.35 | $133.5K |
| Sep 2, 26 | Zhou Rong | officer: SENIOR EVP, PRODUCTION CENTER | S-Sale | 3,187 @ $23.63 | $75.31K |
| Aug 11, 26 | Prins Richard K | director | S-Sale | 7,973 @ $20.30 | $161.9K |
| Aug 7, 26 | Peters William J | director, officer: CFO, EVP & TREASURER | M-Exempt | 5,053 @ $19.79 | $100.00K |
| Aug 7, 26 | Peters William J | director, officer: CFO, EVP & TREASURER | S-Sale | 8,180 @ $22.48 | $183.9K |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
TTM vs. 5-year historical average (annual ratios)
| Metric | AMPH | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 14.4x | 15.7x · sector 20.7x | Discount |
| Forward P/E (FY26E) | 8.5x | EPS est. 2.96 | Discount |
| Price / Book | 1.4x | 2.8x | Discount |
| Price / Sales | 1.5x | 2.8x | Discount |
| EV / EBITDA | 8.0x | 9.9x | Discount |
| Return on equity | 10.1% | — | Healthy |
| Gross margin | 47.7% | 50.1% | In line |
| Debt / Equity | 0.90 | 0.62 | Moderate |
| Piotroski / Altman Z | 6/9 | Z 2.14 | Grey zone |
Discounted cash flow model
Stock news · updated daily
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Amphastar Pharmaceuticals (NASDAQ: AMPH - Get Free Report) and Enanta Pharmaceuticals (NASDAQ: ENTA - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation. Valuation and Earnings This table compares Amphastar
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | 0.62 | 0.91 | Beat 46.8% | $183.9M |
| May 7, 2026 | 0.70 | 0.42 | Miss -40.0% | $171.2M |
| Feb 26, 2026 | 0.90 | 0.73 | Miss -19.2% | $183.1M |
| Nov 6, 2025 | 0.77 | 0.93 | Beat 20.8% | $191.8M |
| Aug 7, 2025 | 0.71 | 0.85 | Beat 19.7% | $174.4M |
| May 7, 2025 | 0.66 | 0.74 | Beat 12.1% | $170.5M |
| 4 | Aug 11, 2026 | 2026-08-11 16:57:01 | View |
| 10-Q | Aug 6, 2026 | 2026-08-06 16:50:49 | View |
| 8-K | Aug 6, 2026 | 2026-08-06 16:32:07 | View |
| SC 13G | Jul 14, 2026 | 2026-07-14 13:27:06 | View |
| 4 | Jul 13, 2026 | 2026-07-13 19:38:01 | View |
| 3 | Jul 13, 2026 | 2026-07-13 19:36:13 | View |
Proxy statement (DEF 14A) disclosures